acute cellular rejection

a·cute cel·lu·lar re·jec·tion

graft rejection that usually begins within 10 days after a graft has been transplanted into a genetically dissimilar host. Lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages that cause tissue damage. See: primary rejection.
Synonym(s): acute rejection
Mentioned in ?
References in periodicals archive ?
AlloMap Molecular Expression Testing is a gene expression test that uses a simple, noninvasive method of blood sample collection and can be used to reliably indicate the low probability of acute cellular rejection in stable heart transplant recipients.
IMAGE is a multicenter, randomized clinical trial of 602 heart transplant patients comparing XDx's AlloMap Molecular Expression Testing, a noninvasive rejection surveillance method utilizing gene expression profiling testing, to routine endomyocardial biopsy surveillance to monitor acute cellular rejection in cardiac transplant recipients.
Tuesday, June 3, 2008 -- "Impact of Cylex immune cell function assay in predicting acute cellular rejection and recurrence of HCV in liver transplantation" (K.
a molecular diagnostics company focused on noninvasive gene expression tests to monitor immune-mediated conditions, today announced that clinical investigators have presented results demonstrating the potential for extended utility of AlloMap[R], the company's non-invasive genomic-based test to rule-out acute cellular rejection in heart transplant patients.
Data from the study (Abstract 351) shows that the immune responses of lung transplant recipients can result in novel molecular signatures identifying the absence or presence of acute cellular rejection (ACR).
Data from a recent study show that AlloMap testing, a non-invasive method to detect the absence of acute cellular rejection in heart transplant recipients can now be used as early as two months post-transplant to rule out rejection.
MADRID, Spain, April 7 /PRNewswire/ -- XDx, a molecular diagnostics company, today announced that several leading transplant physicians will present data highlighting what the future may hold for the company's first product, AlloMap(TM) molecular expression testing, a non-invasive method to detect the absence of acute cellular rejection in heart transplant patients by measuring gene expression in a patients' peripheral blood.
Primary endpoints in the study were clinically significant differences in acute cellular rejection (ACR) and/or clinically significant differences in hepatitis C recurrence.
AlloMap is FDA cleared as a non-invasive gene expression test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with a standard clinical assessment.
AlloMap is a patented, gene expression test that uses a simple, noninvasive method of blood sample collection and can be used to reliably indicate the low probability of acute cellular rejection in stable heart transplant recipients.
Meyer's experience at larger public and emerging-growth private life sciences companies will immediately benefit our business development and partnering activities, which will build on the recent positive results from the IMAGE Study for XDx's AlloMap([R]) and the inclusion of AlloMap for the non-invasive monitoring of acute cellular rejection in the inaugural International Society for Heart & Lung Transplantation Guidelines for the care of heart transplant recipients," said Pierre Cassigneul, President and Chief Executive Officer of XDx.
According to the ISHLT guidelines, Gene Expression Profiling (AlloMap) can be used to rule out the presence of acute cellular rejection (ACR) of grade 2R or greater in appropriate low-risk patients, between six months and five years after heart transplantation.

Full browser ?